Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02981316 · ClinicalTrials.gov registry record · Phase 1
Treatment of Recurrent Clostridium Difficile Infection With RBX7455
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02981316: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02981316 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02981316, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy and safety of RBX7455 for the treatment of recurrent CDI in subjects who have had at least one recurrence after a primary episode (i.e., at least two episodes) and have completed at least two rounds of standard-of-care oral antibiotic therapy.
Interventions
- BIOLOGICAL RBX7455
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-11 |
| Est. Completion | 2020-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02981316
The ClinicalTrials.gov registry entry for NCT02981316 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RBX7455 is the first listed.
NCT02981316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02981316 about?
NCT02981316 is a clinical study titled "Treatment of Recurrent Clostridium Difficile Infection With RBX7455". The purpose of this study is to demonstrate the efficacy and safety of RBX7455 for the treatment of recurrent CDI in subjects who have had at least one recurrence after a primary episode (i.e., at least two episodes) and have completed at least two rounds of standard-of-care oral antibiotic therapy.
What is the current status of trial NCT02981316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-11. Estimated completion is 2020-07-22.
What interventions are being tested in trial NCT02981316?
The interventions under investigation include: RBX7455 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02981316?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.